سعر مونجارو حقن 2.5 مجم/0.5 مل 2026

Mounjaro (tirzepatide) 2.5 mg subcutaneous injection. Sheet name describes '4 single dose prefilled pens'; Egyptian launch reports Mounjaro KwikPen as 1 multi-dose pen providing 4 weekly doses. Packaging format may differ from US 4× single-dose pens.

• Adjunct to diet and exercise to improve glycemic control in adults (and pediatric patients ≥10 years per US label) with type 2 diabetes mellitus; US label also: reduce risk of major adverse CV events in adults with T2DM at high CV risk.Population: Adults with T2DM (confirm Egyptian approved populations)DailyMed — MOUNJARO (tirzepatide) injection [Eli Lilly]

• Most common (≥5%): nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, abdominal pain.International label, same product · DailyMed — MOUNJARO (tirzepatide) injection [Eli Lilly]

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); serious hypersensitivity to tirzepatide or excipients.International label, same product · DailyMed — MOUNJARO (tirzepatide) injection [Eli Lilly]

• BOXED WARNING: thyroid C-cell tumors in rats — unknown human relevance; contraindicated in MTC/MEN2. Pancreatitis; hypoglycemia with insulin/secretagogues; severe GI reactions; acute kidney injury from dehydration; gallbladder disease; diabetic retinopathy complications; pulmonary aspiration risk with anesthesia; never share KwikPen.International label, same product · DailyMed — MOUNJARO (tirzepatide) injection [Eli Lilly]

• Insulin secretagogues / insulinMajorIncreased risk of hypoglycemia. Management: Consider reducing dose of secretagogue or insulin when initiating tirzepatide.DailyMed — MOUNJARO (tirzepatide) injection [Eli Lilly]

• May cause fetal harm based on animal data; use only if benefit justifies risk. May reduce oral contraceptive efficacy — use non-oral or add barrier for 4 weeks after initiation and each escalation.International label, same product · DailyMed — MOUNJARO (tirzepatide) injection [Eli Lilly]

• Tirzepatide: Activates GIP and GLP-1 receptors; enhances glucose-dependent insulin secretion, reduces glucagon, slows gastric emptying, reduces appetite.